Therefore we sought to investigate whether infusion of gene-modified T cells could correct both humoral and cytotoxic immune defects in a Sap-deficient murine model and an in vivo tumor model by using corrected cells from patients. This evidence concerns the gene SH2D1A and neoplasm.